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Aim: To perform an early cost–effectiveness analysis of in vitro expanded myoblasts (IVM) and minced
myofibers versus midurethral slings (MUS) for surgical treatment of female stress urinary incontinence.
Methods: Cost–effectiveness and sensitivity analyses were performed using a decision tree comprising
previously published data and expert opinions. Results & conclusion: In the base case scenario, MUS was
the cost-effective strategy with a negative incremental cost–effectiveness ratio compared with IVM and
a positive incremental cost–effectiveness ratio compared with minced myofibers. However, the sensitivity
analysis indicates that IVM may become an alternative providing greater effect at a higher cost. With
the possibility of becoming more effective, IVM treatment would be advantageous over MUS given its
reduced invasiveness and lower risks of complications.
First draft submitted: 25 August 2018; Accepted for publication: 30 January 2018; Published online:
1 May 2018
Keywords: cell- and tissue-based therapy • economic analysis • healthcare costs • incremental cost–effectiveness
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Urinary incontinence (UI) is a common medical condition that has a negative impact on the quality of life of
individuals of all ages, racial and ethnic groups. The prevalence of UI is about two-to-four-times higher in women
than in men, ranging from 11 to 57% [1]. The most common subtype is stress urinary incontinence (SUI), affecting
roughly 50% of any women with UI [2]. SUI describes a condition where there is an involuntary leak of urine when
intra-abdominal pressure rises, for example, when coughing, sneezing, laughing or during other physical activity.
SUI has not only a severe impact on quality of life but it also places a substantial economic burden on the healthcare
system and society [3–5]. In the USA, for example, it has been estimated that in 1998, the average direct medical
cost of SUI amounted US$5642 per patient, while the indirect workplace expenses were US$4208 [3]. Evidence
suggests that these costs have experienced an age-related increase over the last years [5].
The clinical management of SUI is complex and may involve conservative treatments, such as pelvic floor muscle
training and pharmacotherapy, as well as surgical procedures. Currently, the gold standard for surgical management
of SUI in women is the midurethral sling (MUS), which displays a cure rate of 80–95% [6–8]. While MUS has a high
success rate, 5–20% of the patients will have persisting incontinence thus needing to undergo sling removal and
subsequent treatment [9]. The postoperative complications reach as high as 7.2% for erosion and the risk of getting a
perioperative urinary tract infection is 17.2% [10]. As an alternative to MUS implantation, with the goal of targeting
the underlying etiology rather than relieving the symptoms, cell-based therapies (CBTs) have recently emerged [11].
Among the different modalities of CBT, intraurethral injection of autologous skeletal myoblasts appears as one of
the most promising regenerative therapies for SUI [12]. While various large-scale clinical trials are still ongoing,
results from the initial clinical studies have shown that these approaches appear to be safe and moderately effective.
Remarkably, a recent study has shown that most patients would prefer autologous CBTs rather than surgery for the
treatment of incontinence [13]. These procedures require a biopsy taken from the patient to obtain skeletal muscle
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progenitor cells, which are implanted within the external urethral sphincter either immediately after harvesting as
minced myofibers (MM) [14,15] or after a period of in vitro myoblast (IVM) expansion [16–18].
Whereas demonstration of clinical efficacy is an important part in the assessment of new regenerative medicine
technologies, early health economic evaluations, such as cost-utility analysis, become equally essential for supporting
decision-making [19]. An early evaluation of cost–effectiveness can be conducted to evaluate the potential impact of
new therapeutic agents when all parameters and their values have been determined. It is common in such an early
evaluation that the initial estimates of the model parameters are derived from expert opinion, observational studies,
pilot studies or small clinical trials, as done for this study. Even though long-term evidence from randomized
controlled trials (RCTs) is unavailable, cost–effectiveness estimations of novel treatments are particularly functional
for providing directions in which future research should focus on [20]. Although, early cost–effectiveness modeling
provides valuable insights into the clinical and economic value of new therapeutic agents, it does not directly
provide a conclusive answer to the question of whether the developer should continue the process [21]. The aim of
this study is to estimate the overall cost–effectiveness of CBTs in comparison to the established MUS procedure for
the initial treatment of SUI by conducting an early cost-utility analysis.
Materials & methods
This cost–effectiveness model describes the average costs and the gain in quality-adjusted life years (QALY) between
the three treatment modalities for women with SUI. The calculations are based on a healthcare sector perspective
and the time frame is chosen to be 1 year, as it is expected to account for the vast majority of costs and outcomes
related to the three treatments of SUI. The healthcare sector perspective was chosen to avoid the problem of double
counting of costs, and to focus firmly on resource cost within the healthcare sector. Thus, changes in the use of
resources beyond the healthcare sector, such as workplace productivity loss, patient and family costs, are beyond
the scope of this study. Only relevant costs, the costs that vary between the alternatives, are included in the analysis.
These costs are all estimated in Euros (year 2016–2017 values). The results are presented as pairwise incremental
cost–effectiveness ratios (ICERs), which are the ratios of the difference in costs to the difference in QALYs between
the treatments. A graphical presentation of the same results is shown in a cost–effectiveness plane, where the ICERs
are given by the slopes of the lines between the cost–effectiveness ratios for the alternative treatment modalities.
A decision tree was constructed using Tree Age (2016 version, TreeAge Software, MA, USA), which enabled the
comparison of cost–effectiveness of the three treatments as illustrated in Figure 1. The decision tree was based
on a previously reported model used to assess the cost–effectiveness of conservative versus surgical management
of SUI [22]. A representative population of women with SUI was modeled based on a series of assumptions;
the patients had to be female with uncomplicated and symptomatic SUI who underwent a normal neurologic
examination, had a normal postvoid residual urine volume and were suited for tension-free vaginal tape (TVT)
or transobturator tape (TOT) surgery. TVT and TOT were chosen as the surgical treatment modeled for MUS,
and is referred to as so onwards. The content of the decision model was selected from evidence-based medical
literature and reflects the best-available data on SUI. The available evidence was obtained by systematic literature
review using MeSH terms in the PubMed search engine. Key literature on the CBTs was found using ((“Myoblasts”
[Mesh]) AND “Urinary Incontinence, Stress” [Mesh]), and ((“Urinary Incontinence, Stress” [Mesh]) AND “Cell-
and Tissue-Based Therapy” [Mesh]). Specific searches on some probabilities and costs used in the decision tree
were also conducted, as these were unattainable through the systematic literature review. Furthermore, to present
reliable results, the uncertainty of the analysis was measured using a sensitivity analysis to examine the impact of
varying the cure rates of SUI for each of the two CBTs.
Probabilities
It was assumed that the probability for each of the scenarios ‘cured’ and ‘not cured’ was defined as a combined
subjective and objective measure. MUS as surgical treatment for SUI has a combined cure rate of 80.9% as observed
in a RCT conducted by Labrie et al. [23]. Morbidities such as mesh erosion, recurrent SUI, de novo urge incontinence
and urinary retention requiring release included in this model are based on formerly published studies. Within 1
year of MUS surgery, the probability of mesh erosion was 2.24%, and 84.6% had sling excision following mesh
erosion [10,24]. Conservative treatment was modeled as an alternative to sling excision with an estimated base case
of 15.4%. Additionally, it was modeled that 36% of the patients who had sling excision experienced persistent SUI
based on a retrospective cohort study [25]. Base case rates of developing de novo urge after initial treatment with
MUS and postoperative use of anticholinergic medication when having developed urge symptoms as a consequence
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Figure 1. A decision tree modeled with probabilities, health utilities and costs.
MUS: Midurethral sling; SUI: Stress urinary incontinence.
of MUS, was modeled after an RCT, which reported probabilities of 6.4 and 16.5%, respectively [10,26]. Patients
who developed urinary retention after MUS treatment that required sling release were estimated to 6.01% in base
case [10]. Rardin et al. performed a retrospective study investigating the risk of recurrent SUI after conducting
a necessary sling release in which 13% reported having a recurrence of SUI equal to or worse than the initial
baseline [27]. Women with persistent SUI after initial MUS treatment were modeled to receive an additional MUS
treatment or no further treatment. However, if SUI persisted after the second MUS treatment, no further treatment
would be offered. The probability of persistent SUI was calculated to be 9.3%. In this group, any other MUS
problem is included to meet the assumptions of the decision model. After failed MUS, 2.4% were found to receive
a second MUS according to Ford et al. [6]. Cure rate probabilities for IVM were estimated based on three different
studies. Two studies from Mitterberger et al. [16,28], and a third study from Blaganje and Lukanovic [18]. These
studies showed cure rates of 90% (n = 20), 79% (n = 119) and 23.7% (n = 38), respectively. A pooled mean was
calculated from all three resulting in an estimated base case cure rate of 68%. Although there are other studies in
the literature showing similar efficiency for IVM, they were not included here due to lack of definition the ‘cured’
patient population [34,35]. All patients not included in the group of ‘cured’ were added to the group ‘not cured’,
despite having shown improvements. The same criteria for ‘cured’ and ‘not cured’ were applied for each of the
treatments to enable comparison. Based on the study of Blaganje and Lukanovic [18], 23.7% was considered as
the lower limit cure rate while based on Mitterberger et al., 90% was considered as the upper limit [16]. The third
treatment alternative, MM, was modeled with base case data from Gräs et al., who investigated this approach for
SUI treatment in a Phase I/II pilot clinical trial [15]. A possibility of either cure or persistent SUI was modeled with
base case of 25 and 75%, respectively. The base case and lower limit were assumed to be the same. The calculation
was done combining the two groups of ‘improved’ and ‘not cured’. The upper limit was estimated by adding the
‘improved’ to the ‘cured’. All probabilities are shown in Table 1 and used in the decision tree (Figure 1).
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Table 1. Parameters of probabilities for different outcomes.
Parameter Base case Ref.
Probability of cure with MUS 80.9% [23]
Probability of problems after MUS surgery 19.1% [23]
Probability of mesh erosion following MUS surgery 2.24% [24]
Probability of mesh erosion that requires sling revision/excision 84.6% [24]
Probability of cure after sling revision/excision 15.4% [24]
Probability of SUI after sling revision/excision 36% [25]
Probability of sustained SUI after MUS surgery 9.3% Estimated
Probability of reoperation with MUS due to sustained SUI 2.4% [6]
Probability of having de novo urge incontinence after insertion of MUS 6.4% [26]
Probability of receiving anticholinergic medicine as treatment of de novo urge incontinence 16.5% [10]
Probability of urinary retention after MUS insertion that requires release 6.01% [10]
Probability of persistent SUI after sling release 13% [27]
Probability of cure with IVM 68.4% [16,18,28]
Probability of persistent SUI after treatment with IVM 31.6% [16,18,28]
Probability of cure with MM 25% [15]
Probability of persistent SUI after treatment with MM 75% [15]
IVM: In vitro myoblast approach; MM: Minced myofiber approach; MUS: Midurethral sling; SUI: Stress urinary incontinence.
Table 2. Parameters of health utilities for different outcomes.
Parameter Base case Ref.
Health utility value of no incontinence 0.93 [29]
Health utility value for SUI 0.71 [29]
Health utility value for treatment of de novo urge with anticholinergic medication 0.81 [29]
Health utility value for de novo urge after MUS operation 0.74 [29]
Health utility value for repeated MUS operation 0.89 [23,29]
MUS: Midurethral sling; SUI: Stress urinary incontinence.
Effects
Effectiveness values were measured in QALYs and are shown in Table 2. QALY can be used to assess the burden
of a specific disease in relation to healthy subjects or subjects suffering from an unrelated disorder. It is a generic
measure used to estimate the value for money in economic evaluation. One QALY is equivalent to 1 year in perfect
health regardless of age, gender, job and financial circumstances. To estimate the number of gained QALYs, each
life-year is multiplied by the relevant health utility weights reflecting the patients’ relative health states. Health
utility weights can range from 0–1, where 0 represents death and 1 represent perfect health; in theory, it is possible
to have a health utility weight below 0 [36]. Since a 1-year time frame was used in this study, the health utilities
from Mittmann et al. were converted to QALYs [29]. The health utility weight for no postoperative incontinence
was 0.93. This value represents healthy women in the age range 12 to >80. The health utility weight for SUI was
0.71 representing women in the age range 20 to >80. The modeled branches ‘repeated MUS’, ‘anticholinergic
treatment’ for de novo urge and de novo urge with ‘no further treatment’ had a different utility score. The health
utility weight for ‘repeated MUS’ was based on the probabilities for successful MUS, where 81% of the ‘repeated
MUS’ would end up having a health utility weight of 0.93 but 19% would still have a score of 0.71. Summed up,
patients with ‘repeated MUS’ end up having a health utility of 0.89. Based on data from Wu et al. [37], treatment of
de novo urge with ‘anticholinergic medication’ used in the decision tree was 0.81, whereas the health utility value
for de novo urge with ‘no further treatment’ after MUS was 0.74. The calculated QALYs used in the decision tree
are an expression for the utility gained per treatment. Based on a QALY calculation, a gain from receiving a curative
treatment was calculated to be 0.11 proportional gained QALY over a year. It is assumed that cured SUI patients,
despite which of the treatments used, had a gain of 0.11 QALY, as illustrated in the decision tree.
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Table 3. Parameters of costs for different outcomes.
Parameter Base case (€) Ref.
Cost of outpatient MUS 1693 [30]
Cost of sling excision for mesh erosion 1693 [30]
Cost of anticholinergic treatment 442 [31]
Cost of pelvic floor muscle training 66 [32]
Cost of sling release for urinary retention 1693 [30]
Cost of MM 1223 Expert opinions
Cost of IVM 2224 [33]
IVM: In vitro myoblast approach; MM: Minced myofiber approach; MUS: Midurethral sling.
Costs
All costs are summarized in Table 3. It was assumed that each of the three treatments for SUI would be standard
treatment and have identical follow-up periods, to allow for comparison. Furthermore, the analysis was conducted
from a public health system perspective in regard to analyzing the direct costs, thus excluding the extra societal
costs such as loss of employment productivity and future costs. Cost estimates on the MUS treatment are based
on the Danish diagnosis-related group (DRG) rates, which represent the average costs of a defined group in the
healthcare system by the Danish Health and Medicines Authority [30]. Costs related to outpatient MUS were
estimated to €1693 based on DRG 1314 "Simple gynecologic operation" in which "Vaginal uretrocystopexy with sling"
and "Vaginal uretrocystopexy with sling through foramen obturator" are included [30]. The "anticholinergic treatment"
for de novo urge has an estimated cost of €836 based on cost of defined daily dosage for oxybutynine, which is used
as standard drug treatment for urge incontinence in Denmark. Cost related to pulsed magnetic field therapy was
€66, estimated from the price of four visits at a physiotherapist. A visit to a Danish physiotherapist was estimated
to €22.8 for the first visit, and €14.5 for each of the additional three visits. These costs were estimated based
on the reimbursement level from a physiotherapist clinic in Denmark [32]. Based on a study by Nafees [33], who
compared the manufacturing costs for allogeneic versus autologous cell therapies, the cost for IVM was estimated
to be €2224. This value includes the average costs for donor materials, operating the manufacturing facility, cell
expansion, packaging and transfer to the hospital. The surgery costs were estimated as the average between 2016
and 2017 of the Danish DRG rate PG06B "Cystoscopy, complicated or urethral surgery or puncture of the prostate".
A detailed description on how the total cost for IVM was calculated is included as supplementary information
(Supplementary Tables 1 & 2). The cost of MM procedure was estimated to be €1223, considering the treatment
to be coded as the same DRG rate as for MUS, except for the sling material used for MUS. The cost estimations for
CBT procedures have been validated through personal communication with researchers that have been involved in
the respective clinical trials. All base case scenarios values are listed in Tables 1–3.
The cost-utility analysis was further supplemented by one-way sensitivity analyses. Key variables were identified
in the model as the probabilities of cure rates, and reasonable sensitivity ranges for these inputs were determined.
The sensitivity ranges were guided by existing data.
Results
Based on the base case scenarios, the two novel CBTs were compared with the MUS treatment. A negative ICER
was calculated when comparing IVM to MUS (i.e., MUS was better and cheaper than IVM) and an ICER of
€9527/gained QALY when comparing MM to MUS treatment (i.e., MUS was better and cheaper than IVM).
Both ICERs consolidate the MUS treatment as the preferred strategy for treatment of SUI.
Figure 2A shows the base case scenarios for all treatments. It is illustrated that MUS is more effective than the
two CBTs, but more expensive than MM. IVM is both more expensive and less effective than MUS, hence being
dominated and not cost-effective. If the cure rate for the CBTs was ≥0.862, requiring the cure rate for IVM to
increase with 26% from base case values and MM with 345%, they would be the preferred treatments over MUS.
Figure 2B shows a one-way sensitivity analysis with probabilities as variables for IVM. A one-way sensitivity
analysis was also made for MM with probabilities as variable, resulting in a QALY gain of 0.08. Although, this did
not lead to any change in regard to which treatments were to be cost-effective. However, with the probabilities for
IVM being 90%, the QALY gain is 0.10, superior to the 0.09 for MUS. The sensitivity analysis resulted in an ICER
of €42940/per QALY gained for IVM, thus each treatment is €429.4 more expensive with a 0.01 gain in effect.
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Figure 2. Cost–effectiveness analysis for cell-based therapies versus midurethral slings for the treatment of female
stress urinary incontinence. (A) A cost–effectiveness analysis based on the base case scenarios of the three different
treatment approaches. Note that the IVM approach is dominated by the MUS procedure. (B) A cost–effectiveness
analysis based on the sensitivity analysis of IVM with the upper limit scenario. Note that IVM is more effective, but
more expensive.
IVM: In vitro myoblast; MM: Minced myofiber technique; MUS: Midurethral sling.
Furthermore, the sensitivity analysis resulted in an ICER of €57160 saved per QALY loss for MM, resulting in cost
savings on €571.6 per patient with a 0.01 loss in effectiveness. One-way sensitivity analysis was made with cost as
a variable for all treatments, but did also not have a significant impact, as the IVM did not become as inexpensive
as MUS and MUS did not become as costly as IVM. However, if IVM should be less costly than MUS, the cost
would have to decrease with 23.9%.
Discussion
Given the increasing demand of financial resources for the healthcare and taking into account the considerable
economic impact of SUI [3–5], it is critical to perform early cost–effectiveness assessment of potential new regenerative
medicine therapies. In this direction, this study provides a model to assess the cost–effectiveness of CBTs in
comparison to the established MUS therapy for surgical management of SUI in women.
The base case values illustrated in Figure 2A reveal that MM has the least expenditures per treatment but also
the lowest gain in QALY. The sensitivity analysis of MM with an upper limit of probabilities, which gives a QALY
gain of 0.08, did not dominate MUS treatment. With the currently available evidence, it is therefore unlikely that
MM would become an established modality of treatment. On the other hand, IVM is dominated by the MUS
treatment, hence the negative ICER, which indicates that IVM is both costlier and less effective. However, the
one-way sensitivity analysis based on the upper limit cure rate for IVM indicates that IVM may become more
effective as compared with the standard MUS procedure. Furthermore, the sensitivity analysis indicated that IVM
has a QALY gain of 0.10 but is more expensive. In the best-case scenario, IVM may be the preferred option for
providing a greater effect at a higher cost, considering the less invasive nature of the intervention and the reduced
risk of severe complications [38]. In addition, with the rising number of CBTs under development, it is feasible
that the costs of cell expansion will be significantly reduced in the future, further reducing the cost of the IVM
procedure. For allogeneic stem cell-based therapies, the costs for large-scale expansion are currently displaying a
tendency to decrease, mainly due to reduced costs of consumables as the market grows and increased automation of
the process [39]. Although the economics of autologous large-scale expansion is challenged by the strict regulation
of cell-based advanced therapies [40,41], it is worth mentioning that alternative regulatory pathways exist, such as
the Hospital Exemption route in Europe, which allow delivering the treatment to patients at public hospitals at a
smaller, noncommercial scale [42]. Besides the reduced costs, it is likely that the effectiveness of the IVM procedures
will improve as better quality cells become available for clinical use.
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Limitations of the present study
One of the limitations of our model is related to the different measures used to evaluate the outcome of the
different treatments. Indeed, there is a lack of uniform reporting tools to define the outcome of SUI surgical
interventions [43,44]. To circumvent this issue, we assumed that all patients considered ‘cured’ within all treatment
groups, had the same QALY of 0.93 as women without a ‘national population health survey’-defined chronic
condition in the age range of 12 to >80 years. Both CBTs used questionnaires to define ‘cured’, ‘improved’ and
‘not cured’ without using QALY, and while QALY for MUS was available, it was not subgrouped. It is crucial to
consider the possibility of a varying QALY for all three treatments after being cured. It is not certain that a patient’s
QALY after treatment with MUS or CBTs will reach as high as 0.93. In addition, it is notable that MUS only treats
the symptoms of the disease, whereas CBTs target the actual cause, namely degeneration of muscle tissue. This
fact can ultimately have an impact on the long-term effects. In perspective, there is a clear need for a consensus,
for example, using QALY based on the same multiattribute health status classification system as an international
comparable parameter, to promote comparison between studies within the field of UI. Another limitation is related
to the fact that treatments do not usually have the same follow-up period. For instance, one of the studies included
in the IVM group [18] had a follow-up of 6 months, while all other studies (IVM, MUS and MM) had a follow-up
of 1 year. In our model, to allow for comparison, we have therefore assumed that the cure rate reported in this
study remained unchanged 6 months after the study was finished.
Regarding the estimation of costs based on the DRG rates, it is worth mentioning that these rates may not
accurately reflect true costs for one specific procedure. For instance, the rate that defines the cost of MUS is a
"simple gynecologic operation". This rate represents the average costs of a defined group in the healthcare system,
in this case covering 25 different operations. For the IVM procedure, the costs associated with the DRG rate
PG06B may increase if cell injection is accompanied by complementary therapies, such as transvaginal electrical
stimulation [17].
It is also worth discussing that the proposed model of the decision tree and its outcomes is only as strong as the
assumptions and evidence the model is based on. The level of evidence used in this study was RCTs for the MUS
treatment and case series and clinical pilot studies for the CBTs. Occasionally, when strong-evidence data were not
available, the estimates relied on expert opinions. Thus, despite the attempt of building the model with the best
available evidence, the conclusions of this study should be taken with caution.
Conclusion
The economic analysis in this work clearly indicates that MUS therapy is the cost-effective treatment option for
women with SUI. The results were driven by the high success rate of MUS compared with the less established
IVM and MM procedures. However, the sensitivity analysis indicates the potential of IVM as an alternative with
both greater effect and higher costs compared with MUS. With the possibility of becoming more effective, the
IVM treatment would be advantageous compared with MUS given its reduced invasiveness and lower risk of
adverse events. Important economic questions were raised on whether IVM could reduce its production costs and
improve health outcome in pursuit of becoming cost-effective thus attracting further investment. In addition, this
study stresses the need of obtaining generic utility values and cure rate probabilities from RCTs. This will enhance
the ability to develop more accurate cost-utility models, which will allow assessing the best treatment for women
affected by SUI.
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Summary points
• An early economic evaluation is an important part in the overall assessment of regenerative medicine therapies,
providing directions in which future research should focus on.
• In this article, the likely cost–effectiveness of two modalities of cell-based therapy have been compared with the
standard surgical treatment for female stress urinary incontinence.
• Minced myofiber therapy has the least expenditure per treatment but also the lowest gain in quality-adjusted life
years. It is therefore unlikely that this modality would become an established therapy for stress urinary
incontinence.
• In vitro expanded myoblast (IVM) therapy is dominated by the midurethral sling treatment. However, one-way
sensitivity analysis based on the upper limit cure rate shows that IVM may become more effective than
midurethral sling.
• The rising availability of cell-based therapies will likely improve the manufacturing efficiency and costs for
allogeneic cell-based therapies, opening the perspective for IVM to become the cost-effective alternative.
• This study stresses the need of defining standardized outcomes, obtaining generic utility values and cure rate
probabilities from randomized clinical trials, to enhance our ability to develop more accurate cost-utility models.
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